AR093805A1 - Derivados de piridina agonistas del receptor 2 de cannabinoides - Google Patents
Derivados de piridina agonistas del receptor 2 de cannabinoidesInfo
- Publication number
- AR093805A1 AR093805A1 ARP130104505A ARP130104505A AR093805A1 AR 093805 A1 AR093805 A1 AR 093805A1 AR P130104505 A ARP130104505 A AR P130104505A AR P130104505 A ARP130104505 A AR P130104505A AR 093805 A1 AR093805 A1 AR 093805A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- halogen
- hydrogen
- attached
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
Abstract
El compuesto de la fórmula 1 puede utilizarse como medicamento. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R¹ es halógeno, halofenilo, cicloalquilalcoxi, halofenilalquilo, oxetaniloxi, haloalcoxi, halofenilalcoxi o alquiloxetanilalcoxi; R² es halógeno, cicloalquilo, haloazetidinilo, halopirrolidinilo, hidroxioxetanilo, cicloalquenilo, halocicloalquilo o halooxetanilo; uno de R³ y R⁴ es hidrógeno o alquilo y el otro es -(CR⁵R⁶)-(CR⁷R⁸)ₙ-R⁹; o R³ y R⁴ junto con el átomo de nitrógeno, al que están unidos, forman un 2-oxo-5-aza-espiro[3.4]octilo, haloazetidinilo o halopirrolidinilo; R⁵ y R⁶ se eligen con independencia entre hidrógeno, alquilo, cicloalquilalquilo, haloalquilo, cicloalquilo, alquilsulfonilalquilo, fenilalcoxialquilo, hidroxialquilo, haloazetidinilalquilo, haloazetidinilcarbonilo, 2-oxa-6-azaespiro[3.3]-heptanilcarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, aminocarbonilo, azetidinilcarbonilo, oxetanilalquilo y alquiloxetanilo; o R⁵ y R⁶ junto con el átomo de carbono, al que están unidos, forman un cicloalquilo, oxetanilo, oxanilo o dioxotietanilo; R⁷ y R⁸ se eligen con independencia entre hidrógeno, alquilo y cicloalquilo; o R⁷ y R⁸ junto con el átomo de carbono, al que están unidos, forman un cicloalquilo; R⁹ es alquilo, alcoxicarbonilo, hidroxilo, hidroxialquilo, aminocarbonilo, ciano, piridinilo, alquilaminocarbonilo, tiazol-2-ilo, oxazol-2-ilo, 5-alquil-[1,2,4]oxadiazol-3-ilo, alquiltetrazolilo, alquiltiazol-2-ilo, 1H-tetrazolilo, 5-amino-[1,2,4]-oxadiazol-3-ilo, 5-alquil-[1,3,4]-oxadiazol-2-ilo, azetidinilcarbonilo, haloazetidinilcarbonilo, 6-oxa-1-azaespiro[3.3]heptanilo, 5-fenil-[1,3,4]-oxadiazol-2-ilo o haloalquilaminocarbonilo; y n es el número 0 ó 1; con la condición de que si R³ y R⁴ son ambos alquilo al mismo tiempo, entonces R¹ y R² no sean ambos halógeno al mismo tiempo; o una sal o un éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12196029 | 2012-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093805A1 true AR093805A1 (es) | 2015-06-24 |
Family
ID=47290807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104505A AR093805A1 (es) | 2012-12-07 | 2013-12-05 | Derivados de piridina agonistas del receptor 2 de cannabinoides |
Country Status (34)
Country | Link |
---|---|
US (1) | US9409866B2 (es) |
EP (1) | EP2928867B1 (es) |
JP (1) | JP6280132B2 (es) |
KR (1) | KR20150092232A (es) |
CN (1) | CN104837818B (es) |
AR (1) | AR093805A1 (es) |
AU (1) | AU2013354113B2 (es) |
BR (1) | BR112015013124A2 (es) |
CA (1) | CA2890353A1 (es) |
CL (1) | CL2015001537A1 (es) |
CO (1) | CO7350652A2 (es) |
CR (1) | CR20150277A (es) |
DK (1) | DK2928867T3 (es) |
EA (1) | EA027780B1 (es) |
ES (1) | ES2643056T3 (es) |
HK (1) | HK1210147A1 (es) |
HR (1) | HRP20171459T1 (es) |
HU (1) | HUE033898T2 (es) |
IL (1) | IL239074B (es) |
LT (1) | LT2928867T (es) |
MA (1) | MA38238B1 (es) |
MX (1) | MX2015007156A (es) |
MY (1) | MY179412A (es) |
PE (1) | PE20151073A1 (es) |
PH (1) | PH12015501082A1 (es) |
PL (1) | PL2928867T3 (es) |
PT (1) | PT2928867T (es) |
RS (1) | RS56424B1 (es) |
SG (1) | SG11201504475QA (es) |
SI (1) | SI2928867T1 (es) |
TW (1) | TWI629263B (es) |
UA (1) | UA114657C2 (es) |
WO (1) | WO2014086805A1 (es) |
ZA (1) | ZA201503600B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2897513C (en) | 2013-03-07 | 2021-03-16 | F. Hoffmann-La Roche Ag | Pyrazol derivatives |
HUE036934T2 (hu) | 2013-03-26 | 2018-08-28 | Hoffmann La Roche | Új piridin származékok |
WO2014177490A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Purine derivatives as cb2 receptor agonists |
EA028123B1 (ru) | 2013-05-02 | 2017-10-31 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 |
UA116395C2 (uk) | 2013-09-06 | 2018-03-12 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
EA032713B1 (ru) * | 2013-12-30 | 2019-07-31 | Лайфсай Фармасьютикалс, Инк. | Терапевтические ингибирующие соединения |
US10214508B2 (en) * | 2014-06-13 | 2019-02-26 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
WO2016011209A1 (en) * | 2014-07-16 | 2016-01-21 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
WO2016009297A1 (en) * | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
AR103742A1 (es) | 2015-02-25 | 2017-05-31 | Hoffmann La Roche | Derivados de trifluorometilpropanamida |
BR112018011562B1 (pt) * | 2015-12-09 | 2023-05-02 | F. Hoffmann-La Roche Ag | Novos derivados de fenil |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
CN110753690B (zh) * | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
JP7454512B2 (ja) | 2018-06-27 | 2024-03-22 | エフ. ホフマン-ラ ロシュ アーゲー | 優先的カンナビノイド2アゴニストとしてのピリジン及びピラジン誘導体 |
MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
WO2020002314A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
KR20210040034A (ko) | 2018-08-01 | 2021-04-12 | 바실리어 파마슈티카 인터내셔널 리미티드 | 이사부코나조늄 설페이트의 정제 방법 |
US20240067657A1 (en) * | 2020-12-29 | 2024-02-29 | Merck Sharp & Dohme Llc | Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses |
CN117800894A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 饱和环类衍生物、包含其的药物组合物及其医药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7691863B2 (en) | 2006-10-04 | 2010-04-06 | Hoffman-La Roche Inc. | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators |
BRPI0919024A2 (pt) * | 2008-09-25 | 2019-09-24 | Boehringer Ingelheim Int | compostos que seletivamente modulam o receptor cb2 |
WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
-
2013
- 2013-12-04 UA UAA201506689A patent/UA114657C2/uk unknown
- 2013-12-04 US US14/648,412 patent/US9409866B2/en not_active Expired - Fee Related
- 2013-12-04 SG SG11201504475QA patent/SG11201504475QA/en unknown
- 2013-12-04 MY MYPI2015701832A patent/MY179412A/en unknown
- 2013-12-04 EA EA201591008A patent/EA027780B1/ru not_active IP Right Cessation
- 2013-12-04 PT PT137995437T patent/PT2928867T/pt unknown
- 2013-12-04 PL PL13799543T patent/PL2928867T3/pl unknown
- 2013-12-04 SI SI201330805T patent/SI2928867T1/sl unknown
- 2013-12-04 HU HUE13799543A patent/HUE033898T2/en unknown
- 2013-12-04 RS RS20171008A patent/RS56424B1/sr unknown
- 2013-12-04 PE PE2015000755A patent/PE20151073A1/es not_active Application Discontinuation
- 2013-12-04 LT LTEP13799543.7T patent/LT2928867T/lt unknown
- 2013-12-04 DK DK13799543.7T patent/DK2928867T3/en active
- 2013-12-04 CN CN201380063605.9A patent/CN104837818B/zh not_active Expired - Fee Related
- 2013-12-04 BR BR112015013124A patent/BR112015013124A2/pt not_active Application Discontinuation
- 2013-12-04 JP JP2015545791A patent/JP6280132B2/ja not_active Expired - Fee Related
- 2013-12-04 MA MA38238A patent/MA38238B1/fr unknown
- 2013-12-04 CA CA2890353A patent/CA2890353A1/en not_active Abandoned
- 2013-12-04 KR KR1020157017462A patent/KR20150092232A/ko not_active Application Discontinuation
- 2013-12-04 WO PCT/EP2013/075442 patent/WO2014086805A1/en active Application Filing
- 2013-12-04 AU AU2013354113A patent/AU2013354113B2/en not_active Ceased
- 2013-12-04 MX MX2015007156A patent/MX2015007156A/es unknown
- 2013-12-04 ES ES13799543T patent/ES2643056T3/es active Active
- 2013-12-04 EP EP13799543.7A patent/EP2928867B1/en not_active Not-in-force
- 2013-12-05 AR ARP130104505A patent/AR093805A1/es unknown
- 2013-12-06 TW TW102144977A patent/TWI629263B/zh not_active IP Right Cessation
-
2015
- 2015-04-30 CO CO15099182A patent/CO7350652A2/es unknown
- 2015-05-15 PH PH12015501082A patent/PH12015501082A1/en unknown
- 2015-05-21 ZA ZA2015/03600A patent/ZA201503600B/en unknown
- 2015-05-25 CR CR20150277A patent/CR20150277A/es unknown
- 2015-05-28 IL IL239074A patent/IL239074B/en not_active IP Right Cessation
- 2015-06-05 CL CL2015001537A patent/CL2015001537A1/es unknown
- 2015-11-03 HK HK15110829.9A patent/HK1210147A1/xx not_active IP Right Cessation
-
2017
- 2017-09-28 HR HRP20171459TT patent/HRP20171459T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093805A1 (es) | Derivados de piridina agonistas del receptor 2 de cannabinoides | |
AR099932A1 (es) | Derivados de piridina | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
PE20160859A1 (es) | Inhibidores de la quinasa reguladora de la senal de apoptosis | |
AR099933A1 (es) | Derivados heterocíclicos de piridina agonistas de cb2 | |
AR086881A1 (es) | Derivados de picolinamida como agonistas del receptor cb2 | |
AR107009A1 (es) | Derivados de fenilo como agonistas del receptor de canabinoides 2 | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR096152A1 (es) | Derivados de purina | |
PE20130155A1 (es) | Derivados de ariletinilo | |
AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
BR112014014909A2 (pt) | agonistas de tgr5 não sistêmicos | |
AR088625A1 (es) | Derivados de aril-quinolina | |
PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
AR088548A1 (es) | Derivados pirazinicos utiles para tratar enfermedades del aparato cardiovascular y para el tratamiento y/o profilaxis del dolor | |
AR091117A1 (es) | N-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
AR091208A1 (es) | Derivados de piperidina | |
AR102539A1 (es) | Triazolo[4,5-d]pirimidinas | |
AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |